Information about Rilpivirine
Rilpivirine is a nonnucleoside reverse transcriptase inhibitor used in combination with other antiretroviral agents in the therapy of human immunodeficiency virus (HIV) infection.
Liver safety of Rilpivirine
Mechanism of action of Rilpivirine
Rilpivirine (ril" pi vir' een) is an antiretroviral agent that acts by noncompetitive binding to, and inhibition of the HIV reverse transcriptase. Rilpivirine is a nonnucleoside reverse transcriptase inhibitor similar in action to nevirapine, efavirenz, delavirdine and etavirine. In several randomized controlled trials, rilpivirine was found to have similar efficacy to efavirenz when combined with at least two nucleoside analogues (typically tenofovir and emtricitabine). Rilpivirine was the fifth nonnucleoside reverse transcriptase inhibitor approved by the FDA , and current indications are for the treatment of HIV infection in combination with other HIV medications.
Dosage and administration for Rilpivirine
Rilpivirine is available under the brand name Edurant in tablets of 25 mg. The recommended dose is 25 mg orally once daily with a meal. Rilpivirine is also available in a fixed dose combination (25 mg) once a day tablet with emtricitabine (200 mg) and tenofovir disoproxil fumarate (300 mg) under the brand name Complera  and a similar combination with tenofovir alafenamide fumarate (25 mg) under the brand name Odefsey . Antiviral resistance can occur and resistance patterns are similar to, and cross react with those due to other nonnucleoside reverse transcription inhibitors.
Side effects of Rilpivirine
Drugs for HIV Infection, in the Subclass Antiretroviral Agents
- Nonnucleoside Reverse Transcriptase Inhibitors (HIV)
- Nucleoside Analogues (HIV)
- Protease Inhibitors (HIV)
HCV NS5A Inhibitors
HCV NS5B (Polymerase) Inhibitors
- Asunaprevir, Boceprevir, Glecaprevir, Grazoprevir, Paritaprevir, Simeprevir, Telaprevir, Voxilaprevir
Drugs for Herpes Virus Infections (HSV, CMV, others)
Drugs for Influenza